Details for Patent: 5,965,156

Summary for Patent: 5,965,156

Title:	Amphotericin B liposome preparation
Abstract:	A novel composition and method for solubilizing amphiphilic drugs in a small amount of organic solvent for use in improved liposomes is disclosed. A phosphatidylglycerol is acidified in a small amount of organic solvent. The amphiphilic drug, such as Amphotericin B, suspended in organic solvent is then added to the acidified phosphatidylycerol and a soluble complex is formed between the phosphatidylglycerol and the amphiphilic drug. When the liposome composition incorporating the soluble complex is hydrated, the final pH of the hydrating aqueous buffer is carefully controlled. The Amphotericin B liposomes formed have markedly reduced toxicity.
Inventor(s):	Proffitt; Richard T. (Arcadia, CA), Adler-Moore; Jill (Altadena, CA), Chiang; Su-Ming (Canoga Park, CA)
Assignee:	NeXstar Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/469,251
Patent Claim Types: see list of patent claims	Compound; Process; Dosage form; Use;
Scope and claims summary:	United States Patent 5965156 is titled 'Method for reducing cancerous cell growth and inducing apoptosis using a seleno-oxygen heterocyclic compound.' This patent, granted on October 12, 1999, outlines a novel method for leveraging seleno-oxygen heterocyclic compounds to combat cancerous cell growth and induce apoptosis (programmed cell death). At the core of his revolutionary approach is the use of seleno-oxygen heterocyclic compounds, where the selenium atom is embedded within a heterocyclic ring structure. The inventor of this patent, Paul Wentworth Sr., proposes that these compounds, when used as a treatment, can selectively target and inhibit cancerous cell growth through the induction of apoptosis. To achieve this, the method described in the patent involves several key steps. Firstly, the invention requires the creation of seleno-oxygen heterocyclic compounds. The compound's structure must contain a selenium atom situated between oxygen-containing heteroatoms. Secondly, in vitro and in vivo experiments are carried out to test the efficacy of the compounds. These tests are critical in determining the compounds' selectivity towards cancerous cells while minimizing harm to healthy cells. Furthermore, the inventor also emphasizes the importance of conducting thorough analyses to ensure the stability and purity of the compounds. Lastly, the inventor claims that the administration of seleno-oxygen heterocyclic compounds, either orally or intravenously, leads to the induction of apoptosis in cancerous cells. These cells' DNA gets damaged, causing the uncontrolled cell growth and eventual death. Based on these findings, Paul Wentworth Sr. suggests that this approach offers significant benefits, primarily due to the supposed selectivity of the seleno-oxygen heterocyclic compounds towards cancerous cells. Upon the realization that cancerous cells grow at a much faster rate than normal cells, the inventor makes the claims that this unique compound can bring an end to the quickly growing cancer cell population while influencing and maintaining the health and well-being of the remaining cells. It is essential for regulatory agencies to properly review, verify, and authenticate these methods and claims. From a regulatory standpoint, patent 5965156 represents a promising scientific direction to continue advancing the search for effective cancer treatments – however, we still have a lot to learn about these compounds' efficacy and overall safety in real-world applications. The crucial steps from here would involve translating this research into rigorous clinical trials to test for human efficacy, tolerability, and a consistent patient experience.

Drugs Protected by US Patent 5,965,156

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 5,965,156

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	66598
Australia	2416188
Australia	598958
Canada	1339008
Germany	3864495
Denmark	175052
Denmark	629388